Home Biosimilar Antibodies Immunology & Inflammation Immunology & Inflammation related Omalizumab (anti-IgE)
For research use only. Not for use in humans.

Omalizumab (anti-IgE)

Synonyms: Immunoglobulin Epsilon， Ig Epsilon Chain C Region

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.

Omalizumab (anti-IgE)

Click to purchase the isotype control of Omalizumab (anti-IgE)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.
In vivo

Omalizumab (anti-IgE) is effective in controlling the allergic symptoms of allergic rhinitis by lowering inflammatory mediator CysLT levels of nasal lavage in an experimental allergic rhinitis model.
Animal Research
Animal models: Sprague Dawley rats
Dosages: 0.5mg
Administration: s.c.

[1]
References

Product Details

CAS No. 242138-07-4
Isotype Human IgG1
Application Omalizumab (anti-IgE)
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20 mM Arg, pH 5.0
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07059091 RECRUITING Drug: Omalizumab (Xolair®)|Drug: Sodium Chloride (NaCl) 0.9 Chronic Obstructive Pulmonary Disease (COPD); Allergies Johns Hopkins University 2026-02-12 PHASE2
NCT02570984 ACTIVE_NOT_RECRUITING Drug: Omalizumab|Drug: Placebo Asthma Boston Children's Hospital 2018-11-27 PHASE2
NCT05332067 RECRUITING Drug: Omalizumab|Drug: Placebo Asthma in Children; Atopy; Viral Upper Respiratory Infection Children's National Research Institute 2022-05-01 PHASE2
NCT07342803 RECRUITING Allergic Asthma Longbio Pharma 2025-01-25 PHASE2
NCT04763447 RECRUITING Drug: Continuation of OMA treatment Asthma Assistance Publique - Hôpitaux de Paris 2021-05-20 PHASE4
NCT06943534 RECRUITING Drug: 5mg/kg omalizumab injection|Drug: 15mg/kg omalizumab i Allergies; Food Allergy Massachusetts General Hospital 2025-07-03 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.